BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p

Related Keywords

United States ,United Kingdom ,American ,Jonathan Fox ,Bio Cardiorenal ,Julian Gillmore ,European Society Of Cardiology Congress ,American Heart Association Scientific Sessions ,Bridgebio Pharma Inc ,United Kingdom National Amyloidosis Centre ,University College London Centre For Amyloidosis ,Us Social Security Administration ,Bridgebio Pharma ,New England Journal ,Professor Julian Gillmore ,University College London ,United Kingdom National Amyloidosis ,Win Ratio ,Kansas City Cardiomyopathy Questionnaire ,Security Administration ,European Society ,Cardiology Congress ,New Drug Application ,